AOP Orphan will actively call on customers in these additional markets to promote Brinavess.
Cardiome chief commercial officer Karim Lalji noted making Brinavess available in significant Central/Eastern European markets is an important milestone in the company’s agreement with AOP Orphan Pharmaceuticals.
"We are pleased that AOP Orphan has expeditiously obtained the necessary registrations to make the product available in these countries. AOP Orphan has already begun successful commercialization of BRINAVESS in Austria and we look forward to continuing success in these additional markets," Lalji added.
AOP Orphan CEO Dr Rudolf Widmann noted the company is pleased to execute on the commercialization of Brinavess in key Central/Eastern European markets.
"The synergies that exist between BRINAVESS and our cardiovascular franchise have enabled us to rapidly build on our existing customer base by offering a complementary product and developing new customer relationships which are significant to our future growth," Dr Widmann added.